title: Current and future treatment modalities in schizophrenia: novel antipsychotic drugs and cognitive therapy.
abstract: In 60 years of use of antipsychotic drugs in schizophrenia, the only definite advance has been the introduction of clozapine. Some but not all other atypical or second-generation drugs may have small therapeutic advantages over conventional antipsychotics, but this remains controversial. New entrant atypicals seem unlikely to be therapeutically superior to conventional drugs, and glutamatergic drugs have yet to fulfill their theoretical promise. There is considerable current interest in novel mechanisms of antipsychotic action, but no such drugs have yet reached market authorization. A psychotherapeutic intervention, cognitive behavioral therapy has also found a place in the treatment of schizophrenia. However, the size of its effect against psychotic symptoms is small, and current evidence suggests no effect against negative symptoms or in reducing relapse.
authors.affiliation: FIDMAG, Germanes Hospitalàries, and CIBERSAM, C/. Dr. Antoni Pujadas 38, 08830 Sant Boi de Llobregat, Barcelona, Spain.
authors.forename: Peter
authors.initials: P
authors.lastname: J McKenna
authors.forename: Ann M
authors.initials: AM
authors.lastname: Mortimer
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D015928:Cognitive Behavioral Therapy; D006801:Humans; D012559:Schizophrenia / Q000628:therapy*
chemical_list: D014150:Antipsychotic Agents